Last reviewed · How we verify

Prasugrel based standard DAPT — Competitive Intelligence Brief

Prasugrel based standard DAPT (Prasugrel based standard DAPT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist (thienopyridine). Area: Cardiovascular.

marketed P2Y12 receptor antagonist (thienopyridine) P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Prasugrel based standard DAPT (Prasugrel based standard DAPT) — Research Maatschap Cardiologen Rotterdam Zuid. Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prasugrel based standard DAPT TARGET Prasugrel based standard DAPT Research Maatschap Cardiologen Rotterdam Zuid marketed P2Y12 receptor antagonist (thienopyridine) P2Y12 receptor
Rosuvastatin plus clopidogrel Rosuvastatin plus clopidogrel Federal University of São Paulo marketed Statin plus antiplatelet agent combination HMG-CoA reductase; P2Y12 receptor
Clopidogrel treatment Clopidogrel treatment VA Office of Research and Development marketed P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor
placebo, aspirine, clopidogrel placebo, aspirine, clopidogrel University Hospital, Angers marketed Antiplatelet agents Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel)
Clopidogrel 75 Clopidogrel 75 US Department of Veterans Affairs marketed P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor
CYP2C19 genotype guided P2Y12 monotherapy CYP2C19 genotype guided P2Y12 monotherapy St. Antonius Hospital marketed P2Y12 inhibitor (antiplatelet agent) P2Y12 receptor
Ticagrelor followed with Methoxyflurane Ticagrelor followed with Methoxyflurane Collegium Medicum w Bydgoszczy marketed Antiplatelet agent combined with volatile analgesic P2Y12 receptor (ticagrelor); NMDA receptor and other targets (methoxyflurane)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist (thienopyridine) class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  2. Azienda Policlinico Umberto I · 1 drug in this class
  3. Deutsches Herzzentrum Muenchen · 1 drug in this class
  4. Elliot Israel, MD · 1 drug in this class
  5. Research Maatschap Cardiologen Rotterdam Zuid · 1 drug in this class
  6. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prasugrel based standard DAPT — Competitive Intelligence Brief. https://druglandscape.com/ci/prasugrel-based-standard-dapt. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: